Abstract. Somatic mutations of the thyrotropin receptor (TSHR) gene and the gene encoding the α subunit of the stimulatory GTP-binding protein (Gsα) are the main cause for autonomously functioning thyroid nodules (AFTN) in iodine-deficient regions of the world. In iodine-sufficient regions, including Japan, the genetic relevance of AFTN is unclear. In a series of 45 Japanese subjects with AFTN, exons 9 and 10 of the TSHR and exons 7-10 of Gsα, where the activating mutations have been found, were analyzed using direct sequencing. We found 29 somatic mutations: 22 in the TSHR gene and 7 in the Gsα gene. The most frequent mutation in TSHR was Met453Thr (10 cases), followed by clustered residues from codons 630 through 633 on TSHR (7 cases). Mutations of Gsα were detected at codon 201 in 5 cases and at codon 227 in 2 cases. No patients had coexistent TSHR and Gsα mutations in the same nodule. All mutated residues but one, which was deleted at codon 403 on the TSHR gene, are constitutively active. The prevalences of a germline polymorphism of Asp727Glu on the TSHR gene and incidental papillary thyroid carcinoma in thyroid surgical specimens were similar to those reported in other studies. In the present study, more than half of the cases with AFTN had a somatic activating mutation either of the TSHR or Gsα gene, despite their high iodine intake.
Thyroid autonomy is very common in geographic regions with iodine deficiency and accounts for approximately half of all cases of hyperthyroidism [1] . However, iodine supplementation leads to a significant reduction in the frequency of thyroid autonomy in such regions [2] . In regions with sufficient iodine intake such as Japan, with its high consumption of seaweeds [3, 4] , the prevalence of thyroid autonomy is low among patients with hyperthyroidism.
somatic activating mutations have been described in autonomously functioning thyroid nodules (AFTN), first in the gene encoding the α subunit of the stimulatory GTP-binding protein (Gsα) [5] and later in the thyrotropin receptor (TSHR) gene [6] . In both TSHR and Gsα, activating mutations result in constitutive activation of the cAMP cascade, independent of TSH. This in turn leads to clonal expansion of the affected thyroid cells and consequent thyroid autonomy. TSHR mutations comprise approximately 30 different residues, predominantly located in the membrane domain of TSHR, and cause dysfunction in the inhibitory interaction with the ectodomain [6] [7] [8] [9] [10] [11] . In contrast, Gsα mutations affect only 3 amino acid residues (codons 201, 203, and 227) [5, [12] [13] [14] [15] . Substitutions at these critical sites impair GTP hydrolysis, thus maintaining Gsα in the active state [12] . Previous studies mainly enrolled subjects with AFTN and toxic multinodular goiter who lived in the iodine-deficient regions. In previous studies of Japanese subjects, TSHR mutations were identified in none of 45 cases, and in 4 of 10 cases, with AFTN [16, 17] ; only 1 of 28 AFTN had a Gsα mutation [18] .
The prevalence and distribution of somatic TSHR and Gsα mutations have not been investigated in a DNA sequencing Exons 9 and 10 of TSHR and exons 7-10 of Gαs, where the activating mutations have been found in hyperfunctioning nodules, were amplified by polymerase chain reaction as follows: initial denaturation for 2 min (94˚C), followed by 30 cycles of 30 sec at 94˚C, 30 sec at the appropriate annealing temperature, and 90 sec at 72˚C, followed by a final 7-min elongation at 72˚C. The annealing temperature was 60˚C for TSHR exon 9, 55˚C for TSHR exon 10, and 62˚C for Gαs exons 7-10. For amplification of exon 9 of the TSHR, the primers were: forward primer, 5'-tca tct ccc aat taa cct caG G-3'; and reverse primer, 5'-Gct tcc aat ttc ctc tcc ac-3'. The primers for exon 10 of the TSHR were: forward primer, 5'-taG Gct caa Gca atc cac ctG-3'; and reverse primer, 5'-GtG tca tGG Gat tGG aat Gc-3'. For amplification of Gαs exons 7-10, primers were: forward primer, 5'-ttc ttt ttc tcc caG ctt cct-3'; and reverse primer, 5'-GGt tGG tct GGt tGt cct cc-3'. Direct sequencing of PCR products was performed using the Bigdye terminator v1.1 cycle sequencing kit (Applied Biosystems, Foster city, ca) and an automatic ABI 3130 sequencer (Applied Biosystems), using each of the above primers or internal primers for exon 10 of the TSHR, as previously described [19, 20] . results in a series of 45 aFtn, we found 29 somatic mutations: 22 in the TSHR gene and 7 in the Gsα gene (Table 1 ). All mutations were present in a heterozygous state, and no patient had coexistent TSHR and Gsα mutations in the same nodule. All mutations were confined to the hyperfunctioning nodule and were not detected in neighboring normal thyroid parenchyma. Histologically, all 45 AFTN were all composed of adenomatous tissue. A papillary thyroid carcinoma was found incidentally in thyroid surgical specimens from 4 (8.8%) patients; however, none of the carcinomas were found in AFTN (Tables 2 and 3 ). The ultrasound pattern of tissue with TSHR mutations was largely mixed; no relationship was found between the location of the mutation and the size of the nodule or the degree of hyperthyroidism.
TSHR gene mutations were caused by a point mutation that resulted in single amino acid substitutions, large series of patients living in an iodine-sufficient region. The aim of this study was to determine the characteristics of these gene mutations in patients with AFTN at a single institution in Japan.
Patients and Methods

Patients and tissue samples
We studied 45 patients who lived in Kobe or its neighboring areas. In Japan, Kobe is part of an iodine-sufficient region [3] and none of the present patients had any history of low dietary iodine intake or of living in an iodine-deficient areas. They all underwent thyroidectomy for AFTN at our clinic during the period from 2006 through 2008. The patients consisted of 6 males and 39 females, and ages ranged from 22 to 78 years (average, 46.7 years). At diagnosis, all patients had overt or subclinical hyperthyroidism with suppressed TSH levels (Tables 2-4). All patients were TBII-negative. Scintiscan imaging showed increased circumscribed 131 iodine uptake by the single nodule, with suppression of surrounding thyroid tissue. The size and pattern of hyperfunctioning nodules were assessed by ultrasonography. Tissue samples were carefully excised by matching the images from the preoperative ultrasound and scintiscan examinations, and were fresh-frozen in liquid nitrogen. DNA was extracted from the hyperfunctioning nodules and surrounding normal thyroid tissue with a QIAamp DNA mini Kit (Qiagen, Chatsworth, CA). The present study was approved by the ethical committee of Kuma Hospital, and informed consent for the use of samples for research purposes was obtained from all patients before surgery.
Analysis of thyroid function
Concentrations of serum TSH, FT4, and FT3 were measured with a chemiluminescent immunoassay (Architect i2000, Abbot Japan, Tokyo, Japan). TBII activity was measured by TRAb ELISA (Cosmic Corp., Tokyo, Japan). Serum thyroglobulin and antithyroglobulin antibodies were measured with a electro-chemiluminescent immunoassay (ECLusys Tg and ECLusys Anti-Tg; Roche Diagnostic, Mannheim, Germany).
consecutive residues from codons 631 through 633, located in the TM6 segment, were found repeatedly in TSHR. A TSHR polymorphism (Asp727Glu) in the carboxy terminus was identified in both AFTN and adjacent normal thyroid tissues of 10 patients (including 4 patients with a somatic tshr mutation and 1 patient with a somatic Gsα mutation) (Tables 2-4). All Gsα gene mutations were caused by point mutations resultexcept for 2 cases (Table 1) . Among these 2 cases, 1 mutation was caused by a 3-base deletion (CGA) at nucleotides 1206-1208, which resulted in 1 amino acid deletion (Asp at codon 403; Del403); the other was caused by substitution of 2 bases within a triplet (ACC→ATT; Thr632Ile). The most frequent mutation was Met453Thr (10 samples) located in the second transmembrane (TM) segment (Fig. 1 Table 2 . Clinical characteristics in patients with TSHR mutations in AFTN Thr632Ala) and 1 Gsα mutation (Arg201His) for up to 10 Japanese subjects examined [17, 21, 22] . They share 3 same mutations and another amino acid substitution in the corresponding codon in our study. Moreover, our study indicated that frequencies and hot spots of TSHR and Gsα mutations among 45 cases are similar to those reported in recent large studies in iodine-deficient regions [10, 15, 23] . The discrepant findings with initial studies may be due to the technical and methodological differences among studies. We and another group [17] performed DNA analysis by direct sequencing using fresh-frozen tissues from subjects; earlier studies analyzed paraffin-embedded tissues by using the single-strand conformation polymorphism method. DNA extracted from paraffin-embedded tissue yields highly fragmented DNA, which is more difficult to amplify for mutation detection than DNA extracted from frozen tissue [24] . Moreover, single-strand conformation polymorphism is known ing in single amino acid substitutions. The affected residues were detected at codon 201 in 5 cases (Fig. 1 ) and at codon 227 in 2 cases. discussion in the present study, among patients with aFtn, the total somatic mutation frequency was 48.9% in the TSHR gene and 15.6% in the Gsα gene. In Japan, the somatic TSHR and Gsα mutations were the main cause of the AFTN, and all mutated residues but 1 (Del403) on the TSHR are acknowledged as constitutively active forms.
The frequencies of TSHR and Gsα mutations in Japan were initially believed to be much lower than those observed in iodine-deficient areas [16, 18] . Thereafter, several groups reported 4 TSHR mutations (Met453Thr, Ile486Met, Leu512Arg, and Table 4 . Clinical characteristics in patients without TSHR and Gsα mutations in AFTN due is the most common (34%) TSHR mutation [27] . Several studies of human AFTN also observed a relatively high prevalence of Met453Thr, which was not explained by iodine intake [10, 15] . Although the clinical features of patients with Met453Thr are not different from those with other mutations (Tables 2  and 3 ), in vitro study showed that biological activity, including basal cAMP and cell growth, in thyroid cells expressing Met453Thr is higher than in cells expressing other active mutations [28] . Secondly, clustered residues from codons 630 through 633 in the TM6 segment of TSHR accounted for 7 cases (Table  1) . Previous studies have identified this as a hot spot of active TSHR mutations [9, 10, 15, 29] . Naturally occurring Del403 was newly found in 1 AFTN in our series. This residue belongs to the hinge region of the amino terminal extracellular domain and is highly conserved within the family of glycoprotein hormone receptors. In vitro, several substitutions, into be less sensitive than direct sequencing [25] . In addition to the use of a less sensitive technique, analysis of restricted segments (codons 605-659) in exon 10 of TSHR [16] might lead to less frequent estimation of TSHR mutations.
In this study, Met453Thr was the most frequent TSHR mutation. Contamination or sampling imprecision is unlikely to explain the presence of the same mutation in multiple nodules, a finding supported by re-analysis of the samples. Imperfect DNA complementarity is also an inadequate explanation for the high frequency of Met453Thr [15] . Met453 is located near the cytoplasmic end of TM2, which faces the interior of the bundle, surrounded by TM3 and TM7, and is critical to activation of the cAMP pathway [26] . This residue is highly conserved within the family of glycoprotein hormone receptors and among various species. Indeed, in hyperfunctioning thyroid nodules of cats, somatic mutation of the corresponding resi- mutations. This is based on the evidence that iodide inhibits the proliferation of active TSHR mutant-expressing thyroid cells by modification of cAMP pathway [38] . These regulatory systems by iodine may be relevant to the situation that the prevalence of AFTN is low in Japan, despite high frequency of the somatic TSHR and Gsα mutations in AFTN in our study. Our findings indicate that the main cause of AFTN in japan is somatic mutations of the tshr, the most common of which was Met453Thr, followed by clustering residues in TM6. Although iodine intake may prevent hyperthyroidism due to thyroid autonomy, the molecular prevalence, with respect to TSHR and Gsα, is similar to that observed in iodine-deficient regions (Fig. 2) .
Acknowledgments
We thank all surgical staffs in Kuma hospital for providing tissue samples. This work was supported in part by Medical Research Fund of Hyogo Medical Association (MRF-H-10-8).
cluding Asp403Ala, Asp403Glu, and Asp403Leu are associated with markedly higher basal cAMP accumulation (1.9-6.7 fold) relative to wild-type TSHR [30, 31] . These data suggest that Del403 is likely a new active TSHR mutation, but further in vitro studies are required. With respect to the prevalence of a germline polymorphism of Asp727Glu in the TSHR gene and the presence of incidental papillary thyroid carcinoma in thyroid surgical specimens, our results confirm the findings of previous studies [32] [33] [34] .
iodine and h 2 o 2 are essential substrates in the thyroid hormone synthesis. Change of iodine concentration affects h 2 o 2 generation in the thyroid: high levels of iodine reduce H 2 o 2 generation through inhibition of NADPH oxidase activity in vitro and in vivo [35, 36] . Besides, H 2 o 2 is a major source of free radicals and reactive oxygen species, which can result in DNA damage and somatic mutation in the thyroid [37] . Therefore, high iodine intake may contribute to protection from genomic dna damage in the thyroid, and total mutation events, including TSHR and Gsα genes, may be less likely. Another significant point is that high iodine intake may contribute to inhibition of hyperthyroidism, even in the presence of somatic TSHR
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